KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Equity Income (2021 - 2025)

Vir Biotechnology (VIR) has disclosed Equity Income for 5 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • Quarterly Equity Income fell 119.37% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 131.5% year-over-year, with the annual reading at $1.7 million for FY2025, 131.28% up from the prior year.
  • Equity Income hit -$2.6 million in Q4 2025 for Vir Biotechnology, down from $1.3 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $164.1 million in Q3 2021 to a low of -$95.0 million in Q1 2022.
  • Historically, Equity Income has averaged $69611.1 across 5 years, with a median of -$2.6 million in 2023.
  • Biggest YoY gain for Equity Income was 208.17% in 2025; the steepest drop was 950.0% in 2025.
  • Year by year, Equity Income stood at -$26.0 million in 2021, then skyrocketed by 134.27% to $8.9 million in 2022, then plummeted by 111.26% to -$1.0 million in 2023, then decreased by 16.73% to -$1.2 million in 2024, then crashed by 119.37% to -$2.6 million in 2025.
  • Business Quant data shows Equity Income for VIR at -$2.6 million in Q4 2025, $1.3 million in Q3 2025, and -$3.4 million in Q2 2025.